MyD88
MYD88proteinMyD88 transduces toll-like-receptor signals that drive monocyte recruitment and vascular inflammation destabilizing atherosclerotic plaques.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleTLR-dependent inflammatory signaling driving monocyte recruitment and plaque inflammation.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000172936
Type I vs Type II discrimination
ScoresType-II-associated
R — rupture / Type-I—
C — confounder / Type-II50
A — assay feasibility68
E — evidence strength49
T1DI (composite)11
Specificity differential (R−C)-35
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 1
4tachyarrhythmian/a
5hypoxemia / respiratory failuremag 2
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 1
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 8 supporting references. See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoEMice Fed High-Fat Diet.Drug design, development and therapy · 2022 · PMID 36148321 · doi